Although HER-2 status is an important biomarker in breast cancers, the current study revealed that there is no difference in the expression of autophagy-related proteins between the AR (+)/HER-2 (–) group and AR (+)/HER-2 (+) group, which is compatible with results from a previous study indicating that MABC does not exhibit differences in tumor characteristics according to HER-2 status [38]. Here, ERBB2 is linked to neoplasm.